Is HCA Healthcare (HCA) Overvalued After Q1 2026 EPS Miss and Revenue Beat?

HCA Healthcare Inc. reported mixed Q1 2026 results, with diluted EPS missing estimates at $7.15 against an estimated $7.18, but revenue beating expectations at $19.109 billion. Despite facing atypical seasonality and weather headwinds, the company saw a 4.3% year-over-year revenue increase and a 22% rise in operating cash flow. GuruFocus deems HCA overvalued, with a GF Value of $431.18 versus a current price of $474.03, highlighting concerns about its leverage and insider selling.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin